CXCR3 and neoplasm: Supporting the possible anti-tumor role of CXCR3 and CCR5 and their ligands in PDAC, Gorchs et al. found that an increased CXCR3 ligand expression was associated with an increased number of T cells in tumor-rich areas [126].